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Atypical and severe manifestations 
• Although most chikungunya virus infections result in fever and arthralgia, other clinical manifestations can occur.  
• Atypical or severe clinical manifestations can be due to the direct effects of the virus, immunologic response to the virus, 
drug toxicity, or diseases unrelated to chikungunya virus infection. 
• Some atypical or severe manifestations are more common in certain groups. For example, vesiculobullous lesions, febrile 
seizures, and meningoencephalitis have been reported in infants and young children. 
• Since many atypical and severe clinical manifestations will be unrelated to chikungunya virus infection, healthcare 
providers should consider and evaluate for other etiologies. 
 
 
Reported atypical or severe disease manifestations of chikungunya virus infection* 
System Clinical manifestations 
Neurological 
Meningoencephalitis, encephalopathy, seizures, Guillain-Barré syndrome,  
cerebellar syndrome, paresis, palsies, neuropathy 
Ocular Optic neuritis, iridocyclitis, episcleritis, retinitis, uveitis 
Cardiovascular Myocarditis, pericarditis, heart failure, arrhythmias, hemodynamic instability 
Dermatological 
Photosensitive hyperpigmentation, intertriginous aphthous-like ulcers,  
vesiculobullous dermatosis 
Renal Nephritis, acute renal failure 
Other 
Bleeding dyscrasias, pneumonia, respiratory failure, hepatitis, pancreatitis, syndrome of 
inappropriate secretion of antidiuretic hormone (SIADH), hypoadrenalism 
*Adapted from Rajapakse et al. 
 
 
Atypical or severe dermatologic manifestations of chikungunya virus infections 
 
 
 
 
 
 
 
Bullous lesion on infant’s leg Hyperpigmentation 
  
Risk groups for severe disease 
• Persons at risk for severe disease (e.g., hospitalization) include neonates exposed intrapartum, older adults, and 
persons with underlying medical conditions (e.g., hypertension, diabetes, cardiovascular disease). 
• Mortality is rare and occurs mostly in older adults. 
Pregnant women and newborns 
• Pregnant women infected with chikungunya virus are not at increased risk of atypical or severe disease. 
• Most pregnant women infected with chikungunya virus do not transmit the virus to the fetus.  
• The highest risk occurs when pregnant women are symptomatic during the intrapartum period (i.e., 2 days before to 
2 days after delivery). During the intrapartum period, half of all infected pregnant women will transmit chikungunya 
virus to their fetus.  
• Infants infected intrapartum are often asymptomatic at birth but most develop clinical illness within 7 days after 
delivery. 
• Common symptoms among neonates include fever, pain, rash, and peripheral edema. Some infants develop 
neurologic disease (e.g., meningoencephalitis, cerebral edema, intracranial hemorrhage), hemorrhagic symptoms, or 
myocardial disease.  
• Laboratory abnormalities include elevated liver function tests, reduced platelet and lymphocyte counts, and 
increased prothrombin time.  
• Neonates who suffer from neurologic disease often develop long-term disabilities.  
• There is no evidence that chikungunya virus is transmitted through breast milk. 
Treatment and clinical management 
• Since no specific antiviral therapy is available, treatment is symptomatic  
• Assess hydration and hemodynamic status 
• Provide supportive care as needed and manage complications 
• Evaluate for other serious conditions (e.g., dengue, malaria, bacterial infection) and treat or manage appropriately 
• Use acetaminophen or paracetamol for fever and pain control 
o If inadequate, consider using narcotics or NSAIDs 
o If the patient is suspected of having dengue, do not use aspirin or other NSAIDs (e.g., ibuprofen, naproxen, 
toradol) until the patient has been afebrile ≥48 hours and does not have warning signs for severe dengue* 
Selected references 
• CDC and Pan American Health Organization. Preparedness and response for chikungunya virus introduction in the 
Americas. Washington, DC: Pan American Health Organization, World Health Organization; 2011.  
• Economopoulou A, et al. Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for 
severe disease during the 2005-2006 outbreak on Reunion. Epidemiol Infect 2009;137:534–41. 
• Gerardin P, et al. Multidisciplinary prospective study of mother-to-child chikungunya virus infection on the Island of 
La Reunion. PLoS Med 2008;5(3):e60.  
• Rajapaksa S, et al. Atypical manifestations of chikungunya infection. Trans Royal Soc Trop Med Hyg 2010;104:89-96. 
• Tandale BV, et al. Systemic involvements and fatalities during chikungunya epidemic in India, 2006. J Clin Virol 
2009;46:145–149. 
 
______________________________________________________________________________________________________ 
*Warning signs for severe dengue include severe abdominal pain, persistent vomiting, mucosal bleeding, clinical fluid 
accumulation, lethargy, enlarged liver, and increased hematocrit with decreased platelet count. 
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